Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP Resistance
Phase of Trial: Phase I/II
Latest Information Update: 11 Nov 2017
At a glance
- Drugs Olaparib (Primary) ; Selumetinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 04 Aug 2017 Planned End Date changed from 1 Jul 2026 to 1 Aug 2026.
- 04 Aug 2017 Planned primary completion date changed from 1 Jul 2026 to 1 Aug 2026.
- 04 Aug 2017 Status changed from not yet recruiting to recruiting.